Brokerages expect that American Renal Associates Holdings Inc (NYSE:ARA) will post earnings of $0.01 per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for American Renal Associates’ earnings. American Renal Associates posted earnings of $0.11 per share during the same quarter last year, which would indicate a negative year over year growth rate of 90.9%. The firm is expected to issue its next earnings report on Tuesday, May 14th.
On average, analysts expect that American Renal Associates will report full year earnings of $0.34 per share for the current fiscal year. For the next year, analysts anticipate that the firm will post earnings of $0.39 per share. Zacks’ EPS calculations are an average based on a survey of sell-side research firms that cover American Renal Associates.
Several research firms have commented on ARA. Zacks Investment Research lowered American Renal Associates from a “buy” rating to a “hold” rating in a research note on Friday, January 25th. SunTrust Banks reiterated a “buy” rating and set a $16.00 price objective on shares of American Renal Associates in a research note on Wednesday, January 9th. Barclays set a $9.00 price objective on American Renal Associates and gave the stock a “hold” rating in a research note on Thursday, March 28th. Deutsche Bank started coverage on American Renal Associates in a research note on Thursday, January 3rd. They set a “hold” rating and a $12.00 price objective for the company. Finally, ValuEngine lowered American Renal Associates from a “buy” rating to a “hold” rating in a research report on Tuesday, December 18th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has issued a buy rating to the company’s stock. American Renal Associates presently has an average rating of “Hold” and an average price target of $15.92.
Hedge funds have recently bought and sold shares of the company. MetLife Investment Advisors LLC purchased a new stake in shares of American Renal Associates in the third quarter valued at approximately $230,000. Squarepoint Ops LLC acquired a new position in American Renal Associates during the fourth quarter worth $125,000. Rhumbline Advisers lifted its stake in American Renal Associates by 47.5% during the fourth quarter. Rhumbline Advisers now owns 17,225 shares of the company’s stock worth $198,000 after purchasing an additional 5,549 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its stake in American Renal Associates by 21.2% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 33,900 shares of the company’s stock worth $391,000 after purchasing an additional 5,925 shares in the last quarter. Finally, Two Sigma Advisers LP lifted its stake in American Renal Associates by 51.2% during the fourth quarter. Two Sigma Advisers LP now owns 45,500 shares of the company’s stock worth $524,000 after purchasing an additional 15,400 shares in the last quarter. Institutional investors and hedge funds own 95.34% of the company’s stock.
NYSE:ARA traded down $0.10 during trading hours on Monday, hitting $6.35. 106,266 shares of the stock were exchanged, compared to its average volume of 225,434. American Renal Associates has a 52-week low of $5.63 and a 52-week high of $23.99. The company has a current ratio of 1.03, a quick ratio of 1.00 and a debt-to-equity ratio of 5.48. The firm has a market cap of $209.75 million, a P/E ratio of 10.41 and a beta of 2.01.
American Renal Associates Company Profile
American Renal Associates Holdings, Inc operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease.
See Also: What is a Futures Contract?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.